Answers are grounded in this paper and cite their sources.
This study is the first to report the predictive value of the WHO-defined diagnostic classification in a set of uniformly treated patients with LGG in a clinical trial. Importantly, this post hoc analysis supports the notion that patients with IDH-mutant high-risk LGG regardless of codeletion status receive benefit from the addition of PCV.
No takes yet. Share an insight, caveat, or question.
Bell et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: